SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (982)1/3/2002 9:31:57 AM
From: tuck  Read Replies (2) | Respond to of 1784
 
BDAL again issues strong guidance:

>>BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 3, 2002--Bruker Daltonics Inc. (NASDAQ: BDAL - news) today reported that its new order bookings for life-science systems increased by more than 25% in the fourth quarter 2001, compared to the fourth quarter 2000. For the full year 2001, new life-science systems bookings also increased by more than 25% when compared to the full year 2000.

Frank Laukien, President and CEO, said: ``Our new order bookings in Q4 were excellent, and bode well for our continued growth in 2002. For the full year 2001, our life-science systems bookings growth was led by MALDI-TOF, which includes MALDI-TOF/TOF, with more than 40% growth. Ion trap mass spectrometry (ITMS) grew more than 30% for all ITMS unit bookings, sold either directly by us, or via our strategic ITMS partner Agilent. We believe that we continue to gain market share with both platforms.''

GUIDANCE FOR THE YEAR 2002

For the year 2002, Bruker Daltonics expects revenue growth in the range of 22% to 27%, and earnings growth in the range of 40% to 60%.

``We expect that our financial performance in 2002 will continue the robust top-line and bottom-line growth of 2001,'' commented John Hulburt, Chief Financial Officer. ``From our strong new order bookings in 2001, we have good top-line visibility into the first quarter, and even some visibility into the second quarter of 2002.''<<

snip

Cheers, Tuck



To: tuck who wrote (982)1/8/2002 8:04:05 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 1784
 
OT:PCOP

<<Tuesday January 8, 2:30 pm Eastern Time
Press Release
SOURCE: OrbiMed Advisors LLC
OrbiMed Advisors Reiterates Opposition to Pharmacopeia Acquisition Of Eos Biotechnology, Inc.>>

S. D. Isaly (zudija jedon!),
You are pain in the ass!
Why you don't sell PCOP stake and be done. Who or what is stopping you?

Miljenko